PMID- 36502890
OWN - NLM
STAT- MEDLINE
DCOM- 20230210
LR  - 20230210
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 195
DP  - 2023 Jan
TI  - Fibrosis-4 stage of liver fibrosis predicts cardiovascular outcomes in acute 
      coronary syndrome patients with and without type 2 diabetes mellitus.
PG  - 110206
LID - S0168-8227(22)01020-8 [pii]
LID - 10.1016/j.diabres.2022.110206 [doi]
AB  - AIMS: We aim to analyze the effect of liver fibrosis, assessed by the Fibrosis-4 
      (FIB-4) index, on cardiovascular events in acute coronary syndrome (ACS) patients 
      with and without type 2 diabetes mellitus (T2DM). METHODS: 6563 ACS patients 
      undergoing PCI were analyzed in this study. Patients were divided into three 
      groups according to literature-based FIB-4 cut-offs: < 1.45, 1.45-3.25, 
      and >/= 3.25. RESULTS: During the median 2.4-year follow-up, 270 major adverse 
      cardiac and cerebrovascular events (MACCE) and 194 major bleeding were recorded. 
      Intermediate or high FIB-4 scores were significantly associated with an elevated 
      risk of MACCE, mortality, and MI but not associated with ischemic stroke and 
      major bleeding. Further restricted cubic spline analysis showed that FIB-4 as a 
      continuous variable was positively associated with an increased adjusted risk of 
      MACCE. The results were consistent in subgroups with and without T2DM. 
      CONCLUSIONS: Liver fibrosis staged by FIB-4 was correlated with an increased risk 
      of MACCE, mortality, and MI in ACS patients who underwent PCI with and without 
      T2DM. FIB-4 index may help risk stratification of ACS patients independent of 
      T2DM status.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Song, Jingjing
AU  - Song J
AD  - Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai 
      Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical 
      Sciences and Peking Union Medical College, Beijing, China.
FAU - Liu, Yupeng
AU  - Liu Y
AD  - Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong 
      Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 
      China.
FAU - Chen, Jing
AU  - Chen J
AD  - Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai 
      Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical 
      Sciences and Peking Union Medical College, Beijing, China.
FAU - Yang, Jie
AU  - Yang J
AD  - Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai 
      Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical 
      Sciences and Peking Union Medical College, Beijing, China.
FAU - Wen, Jun
AU  - Wen J
AD  - Department of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai 
      Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical 
      Sciences and Peking Union Medical College, Beijing, China.
FAU - Gao, Jun
AU  - Gao J
AD  - Department of Cardiology and Institute of Vascular Medicine, Peking University 
      Third Hospital, Beijing, China; Key Laboratory of Molecular Cardiovascular 
      Science, Ministry of Education, Beijing, China.
FAU - Shao, Chunli
AU  - Shao C
AD  - Department of Cardiology and Institute of Vascular Medicine, Peking University 
      Third Hospital, Beijing, China; Key Laboratory of Molecular Cardiovascular 
      Science, Ministry of Education, Beijing, China.
FAU - Wang, Wenyao
AU  - Wang W
AD  - Department of Cardiology and Institute of Vascular Medicine, Peking University 
      Third Hospital, Beijing, China; Key Laboratory of Molecular Cardiovascular 
      Science, Ministry of Education, Beijing, China. Electronic address: 
      wwypumc@126.com.
FAU - Tang, Yi-Da
AU  - Tang YD
AD  - Department of Cardiology and Institute of Vascular Medicine, Peking University 
      Third Hospital, Beijing, China; Key Laboratory of Molecular Cardiovascular 
      Science, Ministry of Education, Beijing, China. Electronic address: 
      tangyida@bjmu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20221209
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications
MH  - *Acute Coronary Syndrome/complications
MH  - *Percutaneous Coronary Intervention/methods
MH  - Liver Cirrhosis/complications
MH  - Treatment Outcome
MH  - Risk Factors
OTO - NOTNLM
OT  - ACS
OT  - Adverse outcomes
OT  - Diabetes mellitus
OT  - FIB-4 score
OT  - Mortality
OT  - PCI
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/12/13 06:00
MHDA- 2023/02/11 06:00
CRDT- 2022/12/12 08:56
PHST- 2022/09/05 00:00 [received]
PHST- 2022/10/30 00:00 [revised]
PHST- 2022/12/02 00:00 [accepted]
PHST- 2022/12/13 06:00 [pubmed]
PHST- 2023/02/11 06:00 [medline]
PHST- 2022/12/12 08:56 [entrez]
AID - S0168-8227(22)01020-8 [pii]
AID - 10.1016/j.diabres.2022.110206 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2023 Jan;195:110206. doi: 10.1016/j.diabres.2022.110206. 
      Epub 2022 Dec 9.